Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers

Abstract

The first gene therapy product, recombinant adenovirus human p53 (rAd-p53), has been approved by CFDA since 2013. During these years, most of the clinical trials and the relevant basic research were carried out by Chinese oncologists. Gendicine was proved to be a safe and promising gene therapy drug for patients who suffered from head and neck squamous cell carcinoma (HNSCC). The basic therapeutic theories of gene therapy were totally different from the traditional ones, such as surgeries or radio- and chemotherapy, and the evaluation of treatment outcomes should also be changed simultaneously. However, there still existed a lot of misunderstandings about gene therapy, which resulted in improper administration, insufficient dosage calculation, and treatment cycles, and the treatment outcomes were unsatisfactory, especially for inexperienced oncologists or hospitals. Therefore, we will provide some practical guidance here on the gene therapy of rAd-p53 based on our previous research and experience, which focused on the basic theories and clinical issues, to answer the questions arising during the clinical of gene therapy and to accelerate the development of gene therapy for the benefit of patients bearing malignant tumors.

References

[1] Brody H. Gene therapy. Nature, 2018, 564: S5.

[2] Zhang WW, . The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum. Gene Ther., 2018, 29: 160-179.

[3] Huang, J. Current developments of targeting the p53 signaling pathway for cancer treatment. Pharmacol. Ther. 220, 107720 (2021).

[4] Tang R, Xu Z. Gene therapy: a double-edged sword with great powers. Mol. Cell Biochem., 2020, 474: 73-81.

[5] Hernandez Borrero, L. J. & El-Deiry, W. S. Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochim. Biophys. Acta Rev. Cancer 1876, 188556 (2021).

[6] Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer, 2014, 14: 359-70.

[7] Liu J, Zhang C, Feng Z. Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim Biophys. Sin. (Shanghai), 2014, 46: 170-179.

[8] Pitolli, C. et al. p53-mediated tumor suppression: DNA-damage response and alternative mechanisms. Cancers (Basel) 11, 1983 (2019).

[9] Schweikl H, . 2-Hydroxyethyl methacrylate-induced apoptosis through the ATM- and p53-dependent intrinsic mitochondrial pathway. Biomaterials, 2014, 35: 2890-904.

[10] Jiang L, . Ferroptosis as a p53-mediated activity during tumour suppression. Nature, 2015, 520: 57-62.

[11] Chang CJ, . p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol., 2011, 13: 317-323.

[12] Kim NH, . A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J. Cell Biol., 2011, 195: 417-433.

[13] Sachdeva M, . p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl Acad. Sci. USA, 2009, 106: 3207-12.

[14] Mello SS, . A p53 super-tumor suppressor reveals a tumor suppressive p53-Ptpn14-Yap axis in pancreatic cancer. Cancer Cell, 2017, 32: 460-473.e6.

[15] White E. Autophagy and p53. Cold Spring Harb. Perspect. Med., 2016, 6: a026120.

[16] Mello SS, Attardi LD. Deciphering p53 signaling in tumor suppression. Curr. Opin. Cell Biol., 2018, 51: 65-72.

[17] Pfaff MJ, . Tumor suppressor protein p53 negatively regulates ischemia-induced angiogenesis and arteriogenesis. J. Vasc. Surg., 2018, 68: 222S-233S.e1.

[18] Rufini A, . Senescence and aging: the critical roles of p53. Oncogene, 2013, 32: 5129-5143.

[19] Kalanxhi E, Dahle J. The role of serotonin and p53 status in the radiation-induced bystander effect. Int. J. Radiat. Biol., 2012, 88: 773-776.

[20] Uehara, I. & Tanaka, N. Role of p53 in the regulation of the inflammatory tumor microenvironment and tumor suppression. Cancers (Basel) 10, 219 (2018).

[21] Muñoz-Fontela C, . Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat. Rev. Immunol., 2016, 16: 741-750.

[22] Dunbar, C. E. et al. Gene therapy comes of age. Science 359, eaan4672 (2018).

[23] Misra SK, Bhattacharya S. Physical chemical and biomolecular methods for the optimization of cationic lipid-based lipoplexes in vitro for the gene therapy applications. Methods Mol. Biol., 2016, 1445: 3-17.

[24] Bottermann M, . TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination. Proc. Natl Acad. Sci. USA, 2018, 115: 10440-10445.

[25] Sun W, . Advances in the techniques and methodologies of cancer gene therapy. Disco. Med., 2019, 27: 45-55.

[26] Li Y, . Key points of basic theories and clinical practice in rAd-p53 (Gendicine ™) gene therapy for solid malignant tumors. Expert Opin. Biol. Ther., 2015, 15: 437-454.

[27] Zhang, S.-Y., Lu, Y.-Y. & Peng, Z.-H. In Recent Advances in Cancer Research and Therapy (eds Liu, X.-Y., Pestka, S., & Shi, Y.-F.) 215–243 (Elsevier, 2012).

[28] Zhang WW. Adenoviral vectors: development and application. Expert Opin. Investig. Drugs, 1997, 6: 1419-1457.

[29] Hendrickx R, . Innate immunity to adenovirus. Hum. Gene Ther., 2014, 25: 265-84.

[30] Li Y, . Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial. BMC Med., 2014, 12

[31] Su X, . Effect and safety of recombinant adenovirus-p53 transfer combined with radiotherapy on long-term survival of locally advanced cervical cancer. Hum. Gene Ther., 2016, 27: 1008-1014.

[32] Kunimura N, . Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models. Sci. Rep., 2020, 10

[33] Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther., 2002, 9: 979-986.

[34] Nastiuk KL, Krolewski JJ. Opportunities and challenges in combination gene cancer therapy. Adv. Drug Deliv. Rev., 2016, 98: 35-40.

[35] Hafner A, . The multiple mechanisms that regulate p53 activity and cell fate. Nat. Rev. Mol. Cell Biol., 2019, 20: 199-210.

[36] Ou HL, Schumacher B. DNA damage responses and p53 in the aging process. Blood, 2018, 131: 488-495.

[37] Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb. Perspect. Med., 2016, 6: a026104.

[38] Li T, . Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell, 2012, 149: 1269-1283.

[39] Fischer M. Census and evaluation of p53 target genes. Oncogene, 2017, 36: 3943-3956.

[40] Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur. J. Cancer, 2017, 83: 258-265.

[41] Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu. Rev. Med., 2015, 66: 129-143.

[42] O’Connor MJ. Targeting the DNA damage response in cancer. Mol. Cell, 2015, 60: 547-560.

[43] Talhouk A, . Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer, 2017, 123: 802-813.

[44] Parra-Herran C, . p53, mismatch repair protein, and POLE abnormalities in ovarian clear cell carcinoma: an outcome-based clinicopathologic analysis. Am. J. Surg. Pathol., 2019, 43: 1591-1599.

[45] Kane JR, . Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro Oncol., 2015, 17: ii24-ii36.

[46] Xie Q, . Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo. World J. Gastroenterol., 2016, 22: 7342-7352.

[47] Atencio IA, . Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment. Mol. Ther., 2001, 4: 5-12.

[48] Rodriguez-Ramirez C, Nör JE. p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy. Crit. Rev. Oncog., 2018, 23: 173-187.

[49] Zhang, S. W. et al. Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 cases. Zhonghua Yi Xue Za Zhi 83, 2023–2028 (2003).

[50] Zhang, S. W. et al. [Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma]. Zhonghua Zhong Liu Za Zhi 27, 426–428 (2005).

[51] Liu S, . Randomized, controlled phase II study of post-surgery radiotherapy combined with recombinant adenoviral human p53 gene therapy in treatment of oral cancer. Cancer Gene Ther., 2013, 20: 375-378.

[52] Guan YS, . Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up. J. Zhejiang Univ. Sci. B, 2009, 10: 331-340.

[53] Wang JG, . [Treatment of local advanced non-small cell lung cancer with recombinant human p53 adenovirus combined with radiochemotherapy]. J. GuiYang Med. Coll., 2014, 39: 225-228.

[54] Pan JJ, . Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J. Clin. Oncol., 2009, 27: 799-804.

[55] Liu RR, Ji CY, Chen JC. Clinical effect of recombinant human p53 adv injection (gendicine) in combination with radiotherapy in patients suffering from recurrent nasopharyngeal carcinoma. J. Otolarngol. Ophthal. Shandong Univ., 2010, 24: 13-16.

[56] Si YF, . Recombinant adenovirus P53 agent injection combined with radiotherapy and chemotherapy for intermediate and advanced stage nasopharyngeal carcinoma. ZhongGuo Zhong Liu Lin. Chuang, 2009, 36: 1031-1039.

[57] Guan YS, . p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up. World J. Gastroenterol., 2011, 17: 2143-2149.

[58] Tian G, . Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. Anticancer Drugs, 2009, 20: 389-395.

[59] Yang ZX, . Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol., 2010, 136: 625-30.

[60] Ou SQ, . Recombinant adenovirus-p53 gene therapy combined with transcatheter arterial chemoembolization for p53-positive and p53-negative hepatocellular carcinoma. Chin. J. Inter. Imaging Ther., 2010, 7: 354-357.

[61] Chen S, . Clinical therapeutic effect and biological monitoring of p53 gene in advanced hepatocellular carcinoma. Am. J. Clin. Oncol., 2014, 37: 24-29.

[62] Zhu, J. X. et al. Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53. Chin. J. Cancer Prev. Treat. 17, 126–128 (2010).

[63] Cui HM, . Outcome of patients with recurrent epithelial ovarian carcinoma following treatment with recombinant human adenovirus p53 combined with chemotherapy. Chin. J. Cancer Biother, 2014, 21: 450-454.

[64] Li Y, . A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int. J. Biol. Sci., 2016, 12: 1022-1031.

[65] Heinrich, S. & Lang, H. Neoadjuvant therapy of pancreatic cancer: definitions and benefits. Int. J. Mol. Sci. 18, 1622 (2017).

[66] Schwartz LH, . RECIST 1.1-update and clarification: From the RECIST committee. Eur. J. Cancer, 2016, 62: 132-137.

[67] Schwartz LH, . RECIST 1.1 - standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur. J. Cancer, 2016, 62: 138-145.

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81972538, 81972546, 81972546, 81972538, 81972546, 81972538, 81972546, 81972538, 81972546, 81972538, 81972546, 81972538, 81972546)